Emmaus Life Sciences Inc., a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, has granted NeoImmuneTech Inc. (NIT) an exclusive license to all rights to market, sell and distribute Endari (prescription grade L-glutamine oral powder) and any generic equivalents in sickle cell disease in the U.S., its territories, and Canada in exchange for a upfront payment and a royalty on NIT’s product sales. The deal is subject to NIT’s obtaining the necessary r...